<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-42956" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Timolol</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Barnes</surname>
            <given-names>James</given-names>
          </name>
          <aff>Virginia Commonwealth University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Moshirfar</surname>
            <given-names>Majid</given-names>
          </name>
          <aff>University of Utah/John Moran Eye Center; Hoopes Vision/HDR Research Center; Utah Lions Eye Bank</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>James Barnes declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Majid Moshirfar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>17</day>
          <month>8</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-42956.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Timolol is a &#x003b2;-blocker used to treat conditions such as open-angle glaucoma, ocular hypertension, infantile hemangiomas, hypertension, myocardial infarction, migraine prevention, and atrial fibrillation. This activity&#x000a0;reviews the mechanism of action, administration methods, adverse effects, contraindications, and monitoring of timolol. Understanding timolol's pharmacology is crucial for healthcare professionals to develop tailored treatment strategies for individual patients.</p>
        <p>This educational activity emphasizes the role of an interprofessional healthcare team in effectively managing timolol therapy. By enhancing their knowledge of timolol administration, healthcare professionals can ensure optimal patient care and improve safety and outcomes. The goal is to equip healthcare providers with the necessary skills and knowledge to formulate personalized treatment plans.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Evaluate the mechanism of action of timolol.</p></list-item><list-item><p>Identify the FDA-approved and off-label indications for timolol.</p></list-item><list-item><p>Assess the adverse drug reactions associated with timolol therapy.</p></list-item><list-item><p>Implement effective collaboration and communication among interprofessional team members to improve outcomes and treatment efficacy for patients who might benefit from timolol&#x000a0;therapy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=42956&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=42956">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-42956.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Timolol is a nonselective &#x003b2;-blocker&#x000a0;that may be administered&#x000a0;topically and orally. Topical timolol is&#x000a0;typically prescribed&#x000a0;to reduce intraocular pressure in patients with open-angle glaucoma and ocular hypertension.<xref ref-type="bibr" rid="article-42956.r1">[1]</xref>&#x000a0;Topical timolol also effectively treats and minimizes thin, superficial infantile hemangiomas.<xref ref-type="bibr" rid="article-42956.r2">[2]</xref>&#x000a0;Oral&#x000a0;timolol can be a component of a multi-therapy regimen for treating hypertension, myocardial infarction,&#x000a0;and migraine prophylaxis.<xref ref-type="bibr" rid="article-42956.r3">[3]</xref><xref ref-type="bibr" rid="article-42956.r4">[4]</xref><xref ref-type="bibr" rid="article-42956.r5">[5]</xref>&#x000a0;Administering timolol&#x000a0;as a treatment for atrial fibrillation in adults is currently being debated.<xref ref-type="bibr" rid="article-42956.r6">[6]</xref><xref ref-type="bibr" rid="article-42956.r7">[7]</xref></p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Topical
<list list-type="bullet"><list-item><p>Open-angle glaucoma&#x000a0;<xref ref-type="bibr" rid="article-42956.r8">[8]</xref><xref ref-type="bibr" rid="article-42956.r9">[9]</xref></p></list-item><list-item><p>Ocular hypertension&#x000a0;<xref ref-type="bibr" rid="article-42956.r10">[10]</xref></p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Systemic
<list list-type="bullet"><list-item><p>Hypertension&#x000a0;<xref ref-type="bibr" rid="article-42956.r11">[11]</xref></p></list-item><list-item><p>Myocardial infarction&#x000a0;<xref ref-type="bibr" rid="article-42956.r12">[12]</xref></p></list-item><list-item><p>Migraine prophylaxis&#x000a0;<xref ref-type="bibr" rid="article-42956.r13">[13]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
        <p><bold>Open-angle glaucoma and ocular hypertension:&#x000a0;</bold>The aqueous humor is secreted into the eye by the ciliary body and exits through the trabecular meshwork. Open-angle glaucoma&#x000a0;occurs due to impeded or resisted outflow.<xref ref-type="bibr" rid="article-42956.r14">[14]</xref>&#x000a0;Reduced or absent outflow causes a gradual increase in intraocular pressure until the intraocular pressure increases&#x000a0;above the normal range. If left untreated, this increase in pressure can lead to irreversible damage to the optic nerve and retinal ganglion cells, causing progressive vision loss.<xref ref-type="bibr" rid="article-42956.r14">[14]</xref></p>
        <p>Beta-blockers such as timolol were once the first-line treatment for open-angle glaucoma and ocular hypertension. Today, patients are treated first with a topical prostaglandin such as latanoprost. Topical prostaglandins can effectively reduce intraocular pressure and carry a lower risk for systemic adverse drug reactions than &#x003b2;-blockers.<xref ref-type="bibr" rid="article-42956.r15">[15]</xref>&#x000a0;Timolol is typically&#x000a0;reserved&#x000a0;for patients who respond insufficiently or have a contraindication to topical prostaglandins. For many patients, clinicians can combine timolol with prostaglandins for an enhanced reduction in intraocular pressure.<xref ref-type="bibr" rid="article-42956.r16">[16]</xref></p>
        <p><bold>Hypertension:&#x000a0;</bold>Historically a first-line therapy for treating hypertension, recent reports have rejected &#x003b2;-blockers (ie, timolol) as first-line treatments for hypertension in favor of more effective medications, including diuretics, calcium-channel blockers, and renin-angiotensin system inhibitors.<xref ref-type="bibr" rid="article-42956.r17">[17]</xref>&#x000a0;However, per&#x000a0;the American College of Cardiology/American Heart Association&#x000a0;guidelines, &#x003b2;-blockers such as timolol can be considered&#x000a0;for patients with hypertension and ischemic heart disease.<xref ref-type="bibr" rid="article-42956.r18">[18]</xref></p>
        <p><bold>Myocardial infarction:&#x000a0;</bold>Myocardial infarction&#x000a0;occurs due to a blockage of one or more coronary arteries. Beta-blockers such as timolol increase survival and improve long-term outcomes after myocardial infarction.<xref ref-type="bibr" rid="article-42956.r19">[19]</xref></p>
        <p><bold>Migraine prophylaxis:&#x000a0;</bold>Migraines characteristically present as recurrent moderate to severe headaches&#x000a0;potentially accompanied by phonophobia, photophobia, and nausea. Migraines can cause severe, unilateral throbbing pain, and physical activity can be an aggravating factor. Timolol is an effective medication for preventing migraines.<xref ref-type="bibr" rid="article-42956.r20">[20]</xref></p>
        <p>
<bold>Off-Label Uses </bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Topical: Infantile hemangioma&#x000a0;<xref ref-type="bibr" rid="article-42956.r21">[21]</xref><xref ref-type="bibr" rid="article-42956.r22">[22]</xref></p>
          </list-item>
          <list-item>
            <p>Systemic: Atrial fibrillation (adults)&#x000a0;<xref ref-type="bibr" rid="article-42956.r23">[23]</xref><xref ref-type="bibr" rid="article-42956.r24">[24]</xref></p>
          </list-item>
        </list>
        <p><bold>Infantile hemangiomas:&#x000a0;</bold>Infantile hemangiomas are benign vascular tumors that occur in 4% to 10% of infants. These tumors&#x000a0;typically have a proliferative phase, followed by involution. The resolution of infantile hemangiomas generally occurs before age 4.<xref ref-type="bibr" rid="article-42956.r2">[2]</xref>&#x000a0;Infantile hemangiomas are usually asymptomatic but may sometimes ulcerate, cause disfiguration, affect vision, or cause feeding difficulties, depending on the location.<xref ref-type="bibr" rid="article-42956.r25">[25]</xref>&#x000a0;Topical ophthalmic timolol can effectively treat thin, superficial infantile hemangiomas.<xref ref-type="bibr" rid="article-42956.r2">[2]</xref>&#x000a0;</p>
        <p><bold>Atrial fibrillation:&#x000a0;</bold>Atrial fibrillation is a common rhythm abnormality of the heart. Patients with atrial fibrillation are at an increased risk for many cardiovascular events, including stroke, heart failure, thromboembolism, and cardiovascular-related hospitalizations.<xref ref-type="bibr" rid="article-42956.r26">[26]</xref> Although &#x003b2;-blockers are among the most common agents used to control heart rate for patients with atrial fibrillation, timolol has not been FDA-approved for this purpose. Although timolol effectively regulates heart rate, it is unlikely to restore sinus rhythm.<xref ref-type="bibr" rid="article-42956.r6">[6]</xref><xref ref-type="bibr" rid="article-42956.r7">[7]</xref><xref ref-type="bibr" rid="article-42956.r27">[27]</xref></p>
      </sec>
      <sec id="article-42956.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>
<bold>Open-Angle Glaucoma</bold>
</p>
        <p>The exact mechanism of action by which timolol reduces the intraocular pressure in patients with open-angle glaucoma is unknown. Timolol is thought to inhibit &#x003b2;-receptors on the ciliary epithelium, which normally functions to increase the production of aqueous humor.<xref ref-type="bibr" rid="article-42956.r28">[28]</xref><xref ref-type="bibr" rid="article-42956.r29">[29]</xref> Some researchers have proposed that by inhibiting&#x000a0;these receptors, timolol reduces aqueous humor production and, therefore, reduces intraocular pressure.<xref ref-type="bibr" rid="article-42956.r30">[30]</xref> Researchers have also studied non-adrenergic pathways of timolol to reduce intraocular pressure.<xref ref-type="bibr" rid="article-42956.r31">[31]</xref></p>
        <p>
<bold>Ocular Hypertension</bold>
</p>
        <p>Timolol's mechanism of action in&#x000a0;reducing&#x000a0;intraocular pressure in patients with ocular hypertension is unknown. Still, it appears similar to its mechanism in lowering intraocular pressure for patients with open-angle glaucoma.<xref ref-type="bibr" rid="article-42956.r30">[30]</xref><xref ref-type="bibr" rid="article-42956.r31">[31]</xref><xref ref-type="bibr" rid="article-42956.r32">[32]</xref></p>
        <p>
<bold>Infantile Hemangioma</bold>
</p>
        <p>Timolol is thought&#x000a0;to antagonize &#x003b2;-adrenergic receptors, causing multiple processes, including vasoconstriction, apoptosis stimulation, and angiogenesis inhibition.<xref ref-type="bibr" rid="article-42956.r33">[33]</xref></p>
        <p>
<bold>Hypertension</bold>
</p>
        <p>The sympathetic nervous system is an essential component of blood pressure regulation. Usually, &#x003b2;-1 and &#x003b2;-2 receptors&#x000a0;are activated by endogenous catecholamines. These activated&#x000a0;receptors stimulate their associated G-protein, activating adenylyl cyclase and increasing cyclic-AMP (cAMP) levels.<xref ref-type="bibr" rid="article-42956.r34">[34]</xref>&#x000a0;This secondary messenger&#x000a0;initiates a cascade of reactions in the body, including vasoconstriction and elevated blood pressure. Nonselective &#x003b2;-blockers (eg, timolol) block interactions between endogenous catecholamines and prevent the G-protein cascade from occurring,&#x000a0;reducing&#x000a0;sympathetic tone and decreasing&#x000a0;blood pressure.<xref ref-type="bibr" rid="article-42956.r17">[17]</xref></p>
        <p>
<bold>Myocardial Infarction</bold>
</p>
        <p>There are many mechanisms by which &#x003b2;-blockers can reduce morbidity and mortality in patients after myocardial infarction.<xref ref-type="bibr" rid="article-42956.r35">[35]</xref> For example, &#x003b2;-blockers can reduce myocardial oxygen demand and relieve ischemic chest pain.<xref ref-type="bibr" rid="article-42956.r36">[36]</xref> By blocking the sympathetic receptors in the heart,&#x000a0;timolol decreases heart rate. This induced bradycardia prolongs diastole, allowing for increased perfusion of the heart.<xref ref-type="bibr" rid="article-42956.r37">[37]</xref>&#x000a0;Beta-blockers can inhibit platelet aggregation and thromboxane synthesis and&#x000a0;reduce the rate of atherosclerosis and thromboembolism. They also inhibit cardiac remodeling after myocardial infarction.<xref ref-type="bibr" rid="article-42956.r38">[38]</xref></p>
        <p>
<bold>Migraine Prophylaxis</bold>
</p>
        <p>The exact mechanism of timolol for migraine prevention is unknown. One proposed mechanism involves the antagonism of &#x003b2;-adrenergic receptors, which decreases the synthesis and release of norepinephrine, a key intermediate in the pathophysiology of migraines. Another&#x000a0;mechanism that could&#x000a0;explain&#x000a0;timolol's migraine prophylactic properties is&#x000a0;based on the ability of &#x003b2;-blockers&#x000a0;to regulate the neuronal firing of periaqueductal gray matter using gamma-aminobutyric acid (GABA). Timolol also appears to play a&#x000a0;role in regulating the serotonergic system by inhibiting serotonin (5-HT), another important mediator in the pathophysiologic pathway of migraines. This modulation of serotonin's effects seems to contribute to the ability of &#x003b2;-blockers to reduce the sensitivity of the auditory system, reducing the frequency of migraine attacks. There is also a hypothesis that &#x003b2;-blockers play a significant role in reducing the excitability of the visual system in patients with migraines. Beta-blockers such as timolol are also thought to reduce the spread of signals through the brain, including the cortical spread and the excitability of the ventroposteromedial thalamic nucleus.<xref ref-type="bibr" rid="article-42956.r20">[20]</xref></p>
        <p>
<bold>Atrial Fibrillation</bold>
</p>
        <p>The autonomic nervous system plays a significant role in developing atrial fibrillation. Aberrant&#x000a0;sympathetic tone can stimulate myocyte contraction and promote irregular rhythms in susceptible patients.<xref ref-type="bibr" rid="article-42956.r39">[39]</xref><xref ref-type="bibr" rid="article-42956.r40">[40]</xref>&#x000a0;Beta-blockers help maintain the heart's regular rhythm by decreasing the autonomic tone and, therefore, decreasing sympathetic stimulation of the cardiac myocytes.<xref ref-type="bibr" rid="article-42956.r7">[7]</xref></p>
        <p>
<bold>Pharmacokinetics (Oral)</bold>
</p>
        <p><bold>Absorption:</bold> Timolol maleate is nearly completely absorbed&#x000a0;after oral ingestion, with a bioavailability of ~90%.&#x000a0;The drug is detectable in&#x000a0;plasma within 30 minutes, and peak concentrations are reached approximately 1 to 2 hours after administration.&#x000a0;Timolol&#x000a0;undergoes significant first-pass metabolism, resulting in an oral bioavailability of approximately&#x000a0;half&#x000a0;that achieved with intravenous administration.</p>
        <p><bold>Distribution:</bold> Timolol maleate exhibits low plasma protein binding, with less than 10% bound according to equilibrium dialysis and about 60% bound as determined by ultrafiltration. This indicates that a significant proportion of the drug remains unbound and available in the plasma.</p>
        <p><bold>Metabolism:</bold> Timolol is&#x000a0;primarily metabolized in the liver by the cytochrome P450 enzyme CYP2D6 and other hepatic enzymes.</p>
        <p><bold>Elimination:</bold> Timolol maleate's elimination half-life is approximately 4 hours. The drug and its metabolites are primarily excreted via the kidneys.</p>
        <p>
<bold>Pharmacokinetics (Ocular)</bold>
</p>
        <p><bold>Absorption:</bold>&#x000a0;Timolol maleate ophthalmic solution is systemically absorbed, with bioavailability ranging from 60% to 78%. Peak plasma concentrations (Cmax) are typically attained within 15 minutes&#x000a0;of ocular application. The onset of action usually occurs within 15 to 30 minutes, and the maximum reduction in intraocular pressure (IOP) is typically reached within 1 to 5 hours.</p>
        <p><bold>Distribution:</bold>&#x000a0;Timolol is distributed in several ocular tissues, including the&#x000a0;aqueous humor, retina, choroid, and vitreous body.<xref ref-type="bibr" rid="article-42956.r41">[41]</xref></p>
        <p><bold>Metabolism:</bold>&#x000a0;CYP2D6 is the&#x000a0;primary enzyme&#x000a0;that metabolizes&#x000a0;timolol. Systemic absorption is significant despite ocular application.<xref ref-type="bibr" rid="article-42956.r42">[42]</xref></p>
        <p><bold>Elimination:</bold>&#x000a0;Timolol and its metabolites are predominantly excreted in the urine. The therapeutic effect generally lasts around 24 hours.</p>
      </sec>
      <sec id="article-42956.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths </bold>
</p>
        <p>Timolol's ophthalmic formulation is available&#x000a0;in&#x000a0;0.25% and 0.5% solutions and gels. Oral timolol is available in&#x000a0;5 mg, 10 mg, and 20 mg tablets.</p>
        <p>
<bold>Adult Dosing</bold>
</p>
        <p><bold>Ocular hypertension and open-angle glaucoma:</bold>&#x000a0;One drop of 0.25% gel is administered daily to the affected eye. Alternatively, one drop of the 0.25% solution is applied to the affected eye twice daily. If the response is inadequate, the concentration is increased to 0.5% twice daily in the affected eye. Once the intraocular pressure is controlled, the patient may&#x000a0;resume once-daily dosing.</p>
        <p><bold>Infantile hemangioma:&#x000a0;</bold>One drop of 0.5% timolol gel is applied to the affected area 2 to 3 times daily. Treatment continues until improvement is stable.</p>
        <p><bold>Hypertension:</bold> Oral timolol (10 to 20 mg) is taken twice daily. If the response is inadequate, the dose can be increased incrementally to a maximum of 60 mg daily.</p>
        <p><bold>Myocardial infarction:&#x000a0;</bold>For the secondary prevention of myocardial infarction, 5 mg of oral timolol may be taken twice daily, which can be increased to 10 mg twice daily.</p>
        <p><bold>Migraine prophylaxis:</bold>&#x000a0;Oral timolol (10 mg) is taken twice daily. If the response is inadequate, the dose can be increased to 30 mg daily.</p>
        <p><bold>Atrial fibrillation (off-label):&#x000a0;</bold>The initial dose is 10 mg twice daily, which can be increased incrementally to a maximum of 30 mg twice daily.</p>
        <p><bold>Angina (off-label):</bold> The daily dose is 10 to 60 mg orally divided into&#x000a0;2 or&#x000a0;3 doses.</p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:&#x000a0;</bold>No dosage adjustments for ocular formulation are specified for liver impairment. As timolol is partially metabolized in the liver, dosage adjustments for oral timolol may be required for patients with hepatic insufficiency.</p>
        <p><bold>Renal impairment:&#x000a0;</bold>No dosage adjustments for the ocular formulation are specified for renal impairment. However, due to its primary excretion via the kidneys, oral timolol may require dosage adjustments in individuals with renal insufficiency to avoid drug accumulation and potential toxicity.</p>
        <p><bold>Pregnancy considerations: </bold>Topical timolol is systemically absorbed following ophthalmic administration; during pregnancy, the minimum effective dose should be used with punctual occlusion to minimize fetal exposure.<xref ref-type="bibr" rid="article-42956.r43">[43]</xref>&#x000a0;There are no adequate and well-controlled studies on the effects of systemic timolol in pregnant women. Timolol should be used during pregnancy only if the potential benefits justify the possible risks to the fetus. According to&#x000a0;the American College of Obstetricians and Gynecologists guidelines, labetalol/nifedipine is preferred for hypertensive disorders of pregnancy.<xref ref-type="bibr" rid="article-42956.r44">[44]</xref></p>
        <p><bold>Breastfeeding considerations:&#x000a0;</bold>Due to the variability in timolol excretion into breast milk and the limited data on its safety during lactation, alternative treatments are often preferred, particularly when nursing a newborn or preterm infant. The use of timolol ophthalmic solution by breastfeeding mothers is&#x000a0;thought to pose minimal risk to the infant. However, guidelines suggest gel formulations may be preferable to minimize systemic absorption and potential milk transfer. To further reduce the likelihood of drug exposure to the infant, it is advisable to apply gentle pressure to the nasolacrimal duct for at least one minute following ocular administration and to remove any excess solution with an absorbent tissue.<xref ref-type="bibr" rid="article-42956.r45">[45]</xref></p>
        <p><bold>Pediatric patients: </bold>The safety and efficacy of timolol have not been established in pediatric patients. According to the American Academy of Pediatrics (AAP), clinicians may prescribe topical timolol (off-label) for thin and superficial infantile hemangiomas.<xref ref-type="bibr" rid="article-42956.r46">[46]</xref><xref ref-type="bibr" rid="article-42956.r47">[47]</xref></p>
        <p><bold>Older patients:</bold>&#x000a0;No significant differences in safety or effectiveness have been observed in older adults.</p>
      </sec>
      <sec id="article-42956.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Timolol administration is associated with various adverse reactions, depending on the administration method and ocular and systemic exposure level. The most common adverse reactions are listed below.</p>
        <p>
<bold>Ocular</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Burning</p>
          </list-item>
          <list-item>
            <p>Stinging</p>
          </list-item>
          <list-item>
            <p>Irritation</p>
          </list-item>
          <list-item>
            <p>Dryness</p>
          </list-item>
          <list-item>
            <p>Itching</p>
          </list-item>
          <list-item>
            <p>Watery eyes</p>
          </list-item>
          <list-item>
            <p>Conjunctival hyperemia</p>
          </list-item>
          <list-item>
            <p>Blurry vision</p>
          </list-item>
          <list-item>
            <p>Atrioventricular block&#x000a0;<xref ref-type="bibr" rid="article-42956.r48">[48]</xref></p>
          </list-item>
          <list-item>
            <p>Periocular atopic dermatitis&#x000a0;<xref ref-type="bibr" rid="article-42956.r49">[49]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Systemic</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Bronchospasm</p>
          </list-item>
          <list-item>
            <p>Bronchoconstriction</p>
          </list-item>
          <list-item>
            <p>Bradycardia</p>
          </list-item>
          <list-item>
            <p>Depression</p>
          </list-item>
          <list-item>
            <p>Fatigue</p>
          </list-item>
          <list-item>
            <p>Confusion</p>
          </list-item>
          <list-item>
            <p>Hair loss</p>
          </list-item>
          <list-item>
            <p>Sexual impotence</p>
          </list-item>
          <list-item>
            <p>Disorientation</p>
          </list-item>
          <list-item>
            <p>Elevated low-density cholesterol levels</p>
          </list-item>
          <list-item>
            <p>Headache</p>
          </list-item>
          <list-item>
            <p>Dizziness&#x000a0;<xref ref-type="bibr" rid="article-42956.r16">[16]</xref><xref ref-type="bibr" rid="article-42956.r50">[50]</xref><xref ref-type="bibr" rid="article-42956.r51">[51]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p><bold>Systemic beta-blockers:</bold> Concomitant use of ocular timolol with systemic &#x003b2;-blockers may enhance systemic &#x003b2;-blockade.</p>
        <p><bold>CYP2D6 inhibitors:</bold> Topical timolol can achieve systemic levels that may cause adverse drug reactions. CYP2D6 genetic variants&#x000a0;or&#x000a0;medications affecting CYP2D6 activity can increase this risk. Caution is&#x000a0;advised when coadministering potent CYP2D6 inhibitors (eg, paroxetine, fluoxetine) with ophthalmic timolol.<xref ref-type="bibr" rid="article-42956.r42">[42]</xref> Quinidine can enhance the effects of timolol by inhibiting its metabolism via the CYP2D6 enzyme, leading to increased systemic &#x003b2;-blockade.<xref ref-type="bibr" rid="article-42956.r52">[52]</xref></p>
        <p><bold>Catecholamine-depleting drugs:</bold>&#x000a0;Timolol should be prescribed cautiously for patients taking catecholamine-depleting drugs (eg, reserpine) due to the risk of hypotension and bradycardia.</p>
        <p><bold>Nonsteroidal anti-inflammatory drugs (NSAIDs):</bold> NSAIDs may reduce the antihypertensive effects of systemic &#x003b2;-blockers.<xref ref-type="bibr" rid="article-42956.r53">[53]</xref></p>
        <p><bold>Calcium channel blockers/digoxin:</bold> Caution is&#x000a0;advised&#x000a0;when prescribing calcium channel blockers and &#x003b2;-blockers together, especially for patients with cardiac dysfunction. Hypotension and AV conduction disturbances can occur; dihydropyridines typically&#x000a0;cause&#x000a0;hypotension, and verapamil or diltiazem&#x000a0;typically cause AV conduction delay.<xref ref-type="bibr" rid="article-42956.r54">[54]</xref>&#x000a0;Combining &#x003b2;-blockers with digoxin and either diltiazem or verapamil may prolong AV conduction time.<xref ref-type="bibr" rid="article-42956.r55">[55]</xref></p>
        <p><bold>Clonidine:</bold> Beta-blockers may worsen rebound hypertension after clonidine withdrawal and should be discontinued several days before tapering off clonidine. Beta-blocker therapy may be resumed several days after stopping clonidine.</p>
      </sec>
      <sec id="article-42956.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Timolol is contraindicated&#x000a0;for&#x000a0;patients with a history of asthma, chronic obstructive pulmonary disease (COPD), and other preexisting pulmonary conditions.<xref ref-type="bibr" rid="article-42956.r51">[51]</xref>&#x000a0;Other contraindications for timolol include underlying cardiovascular conditions, including bradycardia, 2nd or 3rd-degree heart block,&#x000a0;and syncope.<xref ref-type="bibr" rid="article-42956.r56">[56]</xref></p>
        <p>
<bold>Box Warnings (Systemic Beta-Blockers)</bold>
</p>
        <p>Patients may experience increased sensitivity to catecholamines if &#x003b2;-blocker therapy is discontinued abruptly, potentially leading to worsened angina or myocardial infarction. To minimize risks when stopping chronically administered timolol, particularly for patients with ischemic heart disease, the dosage should be tapered gradually over weeks. If angina significantly worsens or acute coronary insufficiency occurs, timolol should be promptly resumed, and appropriate steps to manage unstable angina should be taken. Patients should be cautioned against discontinuing or altering therapy without consulting a clinician.&#x000a0;As coronary artery disease remains commonly underdiagnosed, the abrupt discontinuation of timolol should be avoided, even&#x000a0;for patients being treated only for hypertension.<xref ref-type="bibr" rid="article-42956.r57">[57]</xref></p>
        <p>
<bold>Warning and Precautions</bold>
</p>
        <p><bold>Topical product contamination:&#x000a0;</bold>Bacterial keratitis has been linked to using multiple-dose containers of topical ophthalmic products.<xref ref-type="bibr" rid="article-42956.r58">[58]</xref>&#x000a0;Patients with preexisting corneal disease, in particular, should use these medications with caution.</p>
        <p><bold>Choroidal detachment:</bold> Choroidal detachment has been observed following filtration procedures with timolol.<xref ref-type="bibr" rid="article-42956.r59">[59]</xref></p>
        <p><bold>Contact lens precautions: </bold>Some formulations of ocular&#x000a0;timolol include the preservative&#x000a0;benzalkonium chloride, which soft contact lenses can absorb.<xref ref-type="bibr" rid="article-42956.r60">[60]</xref> To prevent potential issues, contact lenses must be removed before applying timolol and should not be reinserted within 15 minutes of application.</p>
        <p><bold>Cardiac failure:</bold> Beta-blockers like timolol may worsen cardiac failure in individuals with preexisting heart conditions. If significant hypotension, bradycardia, or overt cardiogenic shock occurs, timolol should be discontinued.<xref ref-type="bibr" rid="article-42956.r61">[61]</xref></p>
        <p><bold>Obstructive pulmonary disease:</bold>&#x000a0;Nonselective &#x003b2;-blockers like timolol are associated with&#x000a0;COPD exacerbation.<xref ref-type="bibr" rid="article-42956.r62">[62]</xref></p>
        <p><bold>Myasthenia gravis:</bold> Beta-blockers like timolol can exacerbate muscle weakness, particularly in patients with myasthenia gravis.<xref ref-type="bibr" rid="article-42956.r63">[63]</xref></p>
        <p><bold>Hypoglycemia:</bold>&#x000a0;Nonselective &#x003b2;-blockers can mask the symptoms of hypoglycemia in patients with diabetes.<xref ref-type="bibr" rid="article-42956.r64">[64]</xref></p>
      </sec>
      <sec id="article-42956.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Ocular pressure, systemic effects of &#x003b2;-blockade, blood pressure, heart rate, apical pulses, and radial pulses require monitoring while a patient is on timolol. Clinicians should ensure that patients with a history of obstructive airway disease have regular pulmonary function tests and that those with diabetes are monitored closely for blood glucose levels.<xref ref-type="bibr" rid="article-42956.r62">[62]</xref><xref ref-type="bibr" rid="article-42956.r64">[64]</xref></p>
      </sec>
      <sec id="article-42956.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>
<bold>Signs and Symptoms of Overdose</bold>
</p>
        <p>Overdose of &#x003b2;-blockers can cause catecholamine levels to decrease sharply. This effect can lead to various symptoms, including hypotension, bradycardia, hypoglycemia, decreased myocardial contractility and oxygen consumption, and fatigue. Clinicians should closely monitor patients taking anticholinergics or cardiotoxic medicines, as these may potentiate timolol&#x02019;s toxic effects.<xref ref-type="bibr" rid="article-42956.r65">[65]</xref></p>
        <p>
<bold>Management of Overdose</bold>
</p>
        <p>The first step in managing &#x003b2;-blocker overdose is to secure the airway and administer cardiac life support if needed. Oxygen and bronchodilators can be used to treat patients with bronchospasm. Atropine should be given to patients experiencing bradycardia or requiring rapid intubation. Sodium bicarbonate and magnesium sulfate may also prove useful in managing the patient&#x02019;s cardiac symptoms. IV fluids, including dextrose, glucagon, and calcium salts, can be used to treat the patient&#x02019;s metabolic symptoms.&#x000a0;High-dose insulin is used for managing shock caused by &#x003b2;-blocker overdose.<xref ref-type="bibr" rid="article-42956.r66">[66]</xref> Benzodiazepines can be a first-line treatment for any seizures the patient may experience. Gastrointestinal decontamination or administration of activated charcoal can help&#x000a0;reduce the absorption of the &#x003b2;-blocker in the gut.<xref ref-type="bibr" rid="article-42956.r65">[65]</xref></p>
      </sec>
      <sec id="article-42956.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Timolol is a common medication often used in the treatment of open-angle glaucoma and ocular hypertension. All patient care team members, including primary care physicians, emergency departments, nurse practitioners, and pharmacists, must be aware of the contraindications of timolol and its potential adverse effects. The ophthalmic nurse should also ensure the medication works by regularly monitoring the intraocular pressure. Any vision or pressure changes require communication with the ophthalmologist. Ideally, only the ophthalmologist should change the dosage and frequency. Pharmacists can weigh in with medication reconciliation, dose verification, and counseling regarding adverse effects and communicate any concerns to the nurse or prescribing physician. Both the nurse and pharmacist are responsible for instruction on administering ocular formulations effectively. In an overdose, emergency medicine physicians should rapidly stabilize the patient and contact the poison control center if necessary.<xref ref-type="bibr" rid="article-42956.r66">[66]</xref></p>
        <p>The pharmacist should counsel the patient about the medication, the specific dose, and possible adverse effects. Patients should immediately seek help if they overdose or experience severe adverse drug reactions. While timolol is a common and generally well-tolerated medication, an interprofessional team approach to including physicians, specialists, specialty-trained nurses, and pharmacists collaborating as a unit will optimize therapeutic results and minimize adverse events.&#x000a0;An interprofessional team approach and communication among clinicians, pharmacists, and nurses are essential to decreasing potential adverse effects, improving disease course and quality of life, and improving patient outcomes&#x000a0;related&#x000a0;to timolol.</p>
      </sec>
      <sec id="article-42956.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=42956&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=42956">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/42956/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=42956">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-42956.s11">
        <title>References</title>
        <ref id="article-42956.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lazreg</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Merad</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Nouri</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Garout</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Derdour</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ghroud</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kherroubi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Meziane</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Belkacem</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ouhadj</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Baudouin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tiar</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of preservative-free timolol 0.1% gel in open-angle glaucoma and ocular hypertension in treatment-na&#x000ef;ve patients and patients intolerant to other hypotensive medications.</article-title>
            <source>J Fr Ophtalmol</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>41</volume>
            <issue>10</issue>
            <fpage>945</fpage>
            <page-range>945-954</page-range>
            <pub-id pub-id-type="pmid">30477719</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42956.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Danarti</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ariwibowo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Radiono</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Budiyanto</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Topical Timolol Maleate 0.5% for Infantile Hemangioma: Its Effectiveness Compared to Ultrapotent Topical Corticosteroids - A Single-Center Experience of 278 Cases.</article-title>
            <source>Dermatology</source>
            <year>2016</year>
            <volume>232</volume>
            <issue>5</issue>
            <fpage>566</fpage>
            <page-range>566-571</page-range>
            <pub-id pub-id-type="pmid">27592104</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42956.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cruickshank</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>The Role of Beta-Blockers in the Treatment of Hypertension.</article-title>
            <source>Adv Exp Med Biol</source>
            <year>2017</year>
            <volume>956</volume>
            <fpage>149</fpage>
            <page-range>149-166</page-range>
            <pub-id pub-id-type="pmid">27957711</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42956.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fonarow</surname>
                <given-names>GC</given-names>
              </name>
            </person-group>
            <article-title>Beta-blockers for the post-myocardial infarction patient: current clinical evidence and practical considerations.</article-title>
            <source>Rev Cardiovasc Med</source>
            <year>2006</year>
            <season>Winter</season>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-9</page-range>
            <pub-id pub-id-type="pmid">16534490</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42956.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ha</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Gonzalez</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Migraine Headache Prophylaxis.</article-title>
            <source>Am Fam Physician</source>
            <year>2019</year>
            <month>Jan</month>
            <day>01</day>
            <volume>99</volume>
            <issue>1</issue>
            <fpage>17</fpage>
            <page-range>17-24</page-range>
            <pub-id pub-id-type="pmid">30600979</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42956.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sweany</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Moncloa</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Vickers</surname>
                <given-names>FF</given-names>
              </name>
              <name>
                <surname>Zupkis</surname>
                <given-names>RV</given-names>
              </name>
            </person-group>
            <article-title>Antiarrhythmic effects of intravenous timolol in supraventricular arrhythmias.</article-title>
            <source>Clin Pharmacol Ther</source>
            <year>1985</year>
            <month>Feb</month>
            <volume>37</volume>
            <issue>2</issue>
            <fpage>124</fpage>
            <page-range>124-7</page-range>
            <pub-id pub-id-type="pmid">3881206</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42956.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lip</surname>
                <given-names>GY</given-names>
              </name>
              <name>
                <surname>Apostolakis</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Atrial fibrillation (acute onset).</article-title>
            <source>BMJ Clin Evid</source>
            <year>2014</year>
            <month>Nov</month>
            <day>27</day>
            <volume>2014</volume>
            <pub-id pub-id-type="pmid">25430048</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42956.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rouse</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Cipriani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Coleman</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Dickersin</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Network Meta-analysis for Clinical Practice Guidelines: A Case Study on First-Line Medical Therapies for Primary Open-Angle Glaucoma.</article-title>
            <source>Ann Intern Med</source>
            <year>2016</year>
            <month>May</month>
            <day>17</day>
            <volume>164</volume>
            <issue>10</issue>
            <fpage>674</fpage>
            <page-range>674-82</page-range>
            <pub-id pub-id-type="pmid">27088551</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42956.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Steger</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Durai</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Odayappan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Raman</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sruthi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Puthuran</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Venkatesh</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Colantuoni</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Robin</surname>
                <given-names>AL</given-names>
              </name>
            </person-group>
            <article-title>An Evaluation of the Efficacy and Safety of Timolol Maleate 0.5% Microdrops Administered with the Nanodropper.</article-title>
            <source>Ophthalmology</source>
            <year>2024</year>
            <month>Mar</month>
            <day>14</day>
            <pub-id pub-id-type="pmid">38492865</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42956.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Doyle</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Stewart</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Kristoffersen</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Stewart</surname>
                <given-names>WC</given-names>
              </name>
            </person-group>
            <article-title>Meta-analysis of timolol on diurnal and nighttime intraocular pressure and blood pressure.</article-title>
            <source>Eur J Ophthalmol</source>
            <year>2010</year>
            <season>Nov-Dec</season>
            <volume>20</volume>
            <issue>6</issue>
            <fpage>1035</fpage>
            <page-range>1035-41</page-range>
            <pub-id pub-id-type="pmid">20491052</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42956.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gaikwad</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Kshirsagar</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Application of Tablet in Tablet technique to design and characterize immediate and modified release tablets of Timolol maleate.</article-title>
            <source>Heliyon</source>
            <year>2024</year>
            <month>Feb</month>
            <day>15</day>
            <volume>10</volume>
            <issue>3</issue>
            <fpage>e25820</fpage>
            <pub-id pub-id-type="pmid">38356537</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42956.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maslov</surname>
                <given-names>LN</given-names>
              </name>
              <name>
                <surname>Naryzhnaya</surname>
                <given-names>NV</given-names>
              </name>
              <name>
                <surname>Voronkov</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Kurbatov</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Derkachev</surname>
                <given-names>IA</given-names>
              </name>
              <name>
                <surname>Ryabov</surname>
                <given-names>VV</given-names>
              </name>
              <name>
                <surname>Vyshlov</surname>
                <given-names>EV</given-names>
              </name>
              <name>
                <surname>Kolpakov</surname>
                <given-names>VV</given-names>
              </name>
              <name>
                <surname>Tomilova</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Sapozhenkova</surname>
                <given-names>EV</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Fu</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Pei</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>The role of &#x003b2;-adrenergic receptors in the regulation of cardiac tolerance to ischemia/reperfusion. Why do &#x003b2;-adrenergic receptor agonists and antagonists protect the heart?</article-title>
            <source>Fundam Clin Pharmacol</source>
            <year>2024</year>
            <month>Aug</month>
            <volume>38</volume>
            <issue>4</issue>
            <fpage>658</fpage>
            <page-range>658-673</page-range>
            <pub-id pub-id-type="pmid">38423796</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42956.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carcel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Haghdoost</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nanda</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bai</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Atkins</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Torii-Yoshimura</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Clough</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cordato</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Griffiths</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Balicki</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Vidyasagar</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Malavera</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Zagami</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Delcourt</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rodgers</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The effect of blood pressure lowering medications on the prevention of episodic migraine: A systematic review and meta-analysis.</article-title>
            <source>Cephalalgia</source>
            <year>2023</year>
            <month>Jun</month>
            <volume>43</volume>
            <issue>6</issue>
            <fpage>3331024231183166</fpage>
            <pub-id pub-id-type="pmid">37350141</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42956.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weinreb</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Khaw</surname>
                <given-names>PT</given-names>
              </name>
            </person-group>
            <article-title>Primary open-angle glaucoma.</article-title>
            <source>Lancet</source>
            <year>2004</year>
            <month>May</month>
            <day>22</day>
            <volume>363</volume>
            <issue>9422</issue>
            <fpage>1711</fpage>
            <page-range>1711-20</page-range>
            <pub-id pub-id-type="pmid">15158634</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42956.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Orme</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dakin</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kelly</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Loftus</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Mixed treatment comparison and meta-regression of the efficacy and safety of prostaglandin analogues and comparators for primary open-angle glaucoma and ocular hypertension.</article-title>
            <source>Curr Med Res Opin</source>
            <year>2010</year>
            <month>Mar</month>
            <volume>26</volume>
            <issue>3</issue>
            <fpage>511</fpage>
            <page-range>511-28</page-range>
            <pub-id pub-id-type="pmid">20014995</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42956.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Onishchenko</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Isakov</surname>
                <given-names>IN</given-names>
              </name>
              <name>
                <surname>Kolbasko</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Makogon</surname>
                <given-names>SI</given-names>
              </name>
            </person-group>
            <article-title>[Initial combination therapy for primary open-angle glaucoma].</article-title>
            <source>Vestn Oftalmol</source>
            <year>2019</year>
            <volume>135</volume>
            <issue>2</issue>
            <fpage>32</fpage>
            <page-range>32-38</page-range>
            <pub-id pub-id-type="pmid">31215532</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42956.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wiysonge</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Bradley</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Volmink</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mayosi</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Opie</surname>
                <given-names>LH</given-names>
              </name>
            </person-group>
            <article-title>Beta-blockers for hypertension.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2017</year>
            <month>Jan</month>
            <day>20</day>
            <volume>1</volume>
            <issue>1</issue>
            <fpage>CD002003</fpage>
            <pub-id pub-id-type="pmid">28107561</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42956.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Whelton</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Carey</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Aronow</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Casey</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Dennison Himmelfarb</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>DePalma</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Gidding</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jamerson</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>MacLaughlin</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Muntner</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ovbiagele</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Spencer</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Stafford</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Taler</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Williamson</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.</article-title>
            <source>Hypertension</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>71</volume>
            <issue>6</issue>
            <fpage>e13</fpage>
            <page-range>e13-e115</page-range>
            <pub-id pub-id-type="pmid">29133356</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42956.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goldberger</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Bonow</surname>
                <given-names>RO</given-names>
              </name>
              <name>
                <surname>Cuffe</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rosenberg</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Suba&#x0010d;ius</surname>
                <given-names>H</given-names>
              </name>
              <collab>OBTAIN Investigators</collab>
            </person-group>
            <article-title>Effect of Beta-Blocker Dose on Survival After Acute Myocardial Infarction.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2015</year>
            <month>Sep</month>
            <day>29</day>
            <volume>66</volume>
            <issue>13</issue>
            <fpage>1431</fpage>
            <page-range>1431-41</page-range>
            <pub-id pub-id-type="pmid">26403339</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42956.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sprenger</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Viana</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tassorelli</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Current Prophylactic Medications for Migraine and Their Potential Mechanisms of Action.</article-title>
            <source>Neurotherapeutics</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>15</volume>
            <issue>2</issue>
            <fpage>313</fpage>
            <page-range>313-323</page-range>
            <pub-id pub-id-type="pmid">29671241</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42956.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bogomolets</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Wierzbik-Stro&#x00144;ska</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hryshchenko</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bogomolets</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Urgent Treatment of Complicated Ulcerated Infantile Hemangioma with &#x003b2;-Blockers via Telemedicine: A Case Report.</article-title>
            <source>Telemed J E Health</source>
            <year>2024</year>
            <month>Mar</month>
            <volume>30</volume>
            <issue>3</issue>
            <fpage>881</fpage>
            <page-range>881-884</page-range>
            <pub-id pub-id-type="pmid">37651201</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42956.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gomes</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Salazar</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Fraga</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Correia</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Barbosa-Sequeira</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fernandes</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>&#x000c1;lvares</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Banquart Leit&#x000e3;o</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Paiva Coelho</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Management of infantile hemangiomas-experience of a tertiary hospital.</article-title>
            <source>Eur J Pediatr</source>
            <year>2023</year>
            <month>Apr</month>
            <volume>182</volume>
            <issue>4</issue>
            <fpage>1611</fpage>
            <page-range>1611-1618</page-range>
            <pub-id pub-id-type="pmid">36705724</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42956.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Blessberger</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Pritchard</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Fawcett</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Domanovits</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Schlager</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Wildner</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kammler</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Steinwender</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Perioperative beta-blockers for preventing surgery-related mortality and morbidity in adults undergoing cardiac surgery.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2019</year>
            <month>Sep</month>
            <day>23</day>
            <volume>9</volume>
            <issue>9</issue>
            <fpage>CD013435</fpage>
            <pub-id pub-id-type="pmid">31544227</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42956.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Francisco</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Awata</surname>
                <given-names>WMC</given-names>
              </name>
              <name>
                <surname>Lima</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Potje</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Prohaska</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Ceron</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Vale</surname>
                <given-names>GTD</given-names>
              </name>
            </person-group>
            <article-title>Three Generation &#x003b2;-Blockers for Atrial Fibrillation Treatment.</article-title>
            <source>Curr Hypertens Rev</source>
            <year>2023</year>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>34</fpage>
            <page-range>34-41</page-range>
            <pub-id pub-id-type="pmid">35692167</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42956.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>L&#x000e9;aut&#x000e9;-Labr&#x000e8;ze</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Harper</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Hoeger</surname>
                <given-names>PH</given-names>
              </name>
            </person-group>
            <article-title>Infantile haemangioma.</article-title>
            <source>Lancet</source>
            <year>2017</year>
            <month>Jul</month>
            <day>01</day>
            <volume>390</volume>
            <issue>10089</issue>
            <fpage>85</fpage>
            <page-range>85-94</page-range>
            <pub-id pub-id-type="pmid">28089471</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42956.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>January</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Wann</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Alpert</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Calkins</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Cigarroa</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Cleveland</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Conti</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Ellinor</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Ezekowitz</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Field</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Murray</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Sacco</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Stevenson</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>Tchou</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Tracy</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Yancy</surname>
                <given-names>CW</given-names>
              </name>
              <collab>ACC/AHA Task Force Members</collab>
            </person-group>
            <article-title>2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.</article-title>
            <source>Circulation</source>
            <year>2014</year>
            <month>Dec</month>
            <day>02</day>
            <volume>130</volume>
            <issue>23</issue>
            <fpage>e199</fpage>
            <page-range>e199-267</page-range>
            <pub-id pub-id-type="pmid">24682347</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42956.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meyer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lustgarten</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Beta-blockers in atrial fibrillation-trying to make sense of unsettling results.</article-title>
            <source>Europace</source>
            <year>2023</year>
            <month>Feb</month>
            <day>16</day>
            <volume>25</volume>
            <issue>2</issue>
            <fpage>260</fpage>
            <page-range>260-262</page-range>
            <pub-id pub-id-type="pmid">36748952</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42956.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kiland</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Gabelt</surname>
                <given-names>BT</given-names>
              </name>
              <name>
                <surname>Kaufman</surname>
                <given-names>PL</given-names>
              </name>
            </person-group>
            <article-title>Studies on the mechanism of action of timolol and on the effects of suppression and redirection of aqueous flow on outflow facility.</article-title>
            <source>Exp Eye Res</source>
            <year>2004</year>
            <month>Mar</month>
            <volume>78</volume>
            <issue>3</issue>
            <fpage>639</fpage>
            <page-range>639-51</page-range>
            <pub-id pub-id-type="pmid">15106944</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42956.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Watanabe</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chiou</surname>
                <given-names>GC</given-names>
              </name>
            </person-group>
            <article-title>Action mechanism of timolol to lower the intraocular pressure in rabbits.</article-title>
            <source>Ophthalmic Res</source>
            <year>1983</year>
            <volume>15</volume>
            <issue>3</issue>
            <fpage>160</fpage>
            <page-range>160-7</page-range>
            <pub-id pub-id-type="pmid">6314218</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42956.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Neufeld</surname>
                <given-names>AH</given-names>
              </name>
            </person-group>
            <article-title>Experimental studies on the mechanism of action of timolol.</article-title>
            <source>Surv Ophthalmol</source>
            <year>1979</year>
            <season>May-Jun</season>
            <volume>23</volume>
            <issue>6</issue>
            <fpage>363</fpage>
            <page-range>363-70</page-range>
            <pub-id pub-id-type="pmid">223248</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42956.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McLaughlin</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Peart</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Purves</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Carr&#x000e9;</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Peterson-Yantorno</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mitchell</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Macknight</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Civan</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Timolol may inhibit aqueous humor secretion by cAMP-independent action on ciliary epithelial cells.</article-title>
            <source>Am J Physiol Cell Physiol</source>
            <year>2001</year>
            <month>Sep</month>
            <volume>281</volume>
            <issue>3</issue>
            <fpage>C865</fpage>
            <page-range>C865-75</page-range>
            <pub-id pub-id-type="pmid">11502564</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42956.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hoy</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Tafluprost/Timolol: A Review in Open-Angle Glaucoma or Ocular Hypertension.</article-title>
            <source>Drugs</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>75</volume>
            <issue>15</issue>
            <fpage>1807</fpage>
            <page-range>1807-13</page-range>
            <pub-id pub-id-type="pmid">26431840</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42956.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Darrow</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Greene</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Mancini</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Nopper</surname>
                <given-names>AJ</given-names>
              </name>
              <collab>SECTION ON DERMATOLOGY, SECTION ON OTOLARYNGOLOGY&#x02013;HEAD AND NECK SURGERY, and SECTION ON PLASTIC SURGERY</collab>
            </person-group>
            <article-title>Diagnosis and Management of Infantile Hemangioma.</article-title>
            <source>Pediatrics</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>136</volume>
            <issue>4</issue>
            <fpage>e1060</fpage>
            <page-range>e1060-104</page-range>
            <pub-id pub-id-type="pmid">26416931</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42956.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wallukat</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>The beta-adrenergic receptors.</article-title>
            <source>Herz</source>
            <year>2002</year>
            <month>Nov</month>
            <volume>27</volume>
            <issue>7</issue>
            <fpage>683</fpage>
            <page-range>683-90</page-range>
            <pub-id pub-id-type="pmid">12439640</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42956.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>L&#x000f3;pez-Send&#x000f3;n</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Swedberg</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>McMurray</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tamargo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Maggioni</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Dargie</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Tendera</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Waagstein</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kjekshus</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lechat</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Torp-Pedersen</surname>
                <given-names>C</given-names>
              </name>
              <collab>Task ForceOn Beta-Blockers of the European Society of Cardiology</collab>
            </person-group>
            <article-title>Expert consensus document on beta-adrenergic receptor blockers.</article-title>
            <source>Eur Heart J</source>
            <year>2004</year>
            <month>Aug</month>
            <volume>25</volume>
            <issue>15</issue>
            <fpage>1341</fpage>
            <page-range>1341-62</page-range>
            <pub-id pub-id-type="pmid">15288162</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42956.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nuttall</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Toescu</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Kendall</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>beta Blockade after myocardial infarction. Beta blockers have key role in reducing morbidity and mortality after infarction.</article-title>
            <source>BMJ</source>
            <year>2000</year>
            <month>Feb</month>
            <day>26</day>
            <volume>320</volume>
            <issue>7234</issue>
            <fpage>581</fpage>
            <pub-id pub-id-type="pmid">10688573</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42956.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Galcer&#x000e1;-Tom&#x000e1;s</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Castillo-Soria</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Villegas-Garc&#x000ed;a</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Florenciano-S&#x000e1;nchez</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>S&#x000e1;nchez-Villanueva</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>de La Rosa</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;nez-Caballero</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Valent&#x000ed;-Aldeguer</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Jara-P&#x000e9;rez</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>P&#x000e1;rraga-Ram&#x000ed;rez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>L&#x000f3;pez-Mart&#x000ed;nez</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>I&#x000f1;igo-Garc&#x000ed;a</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pic&#x000f3;-Aracil</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Effects of early use of atenolol or captopril on infarct size and ventricular volume: A double-blind comparison in patients with anterior acute myocardial infarction.</article-title>
            <source>Circulation</source>
            <year>2001</year>
            <month>Feb</month>
            <day>13</day>
            <volume>103</volume>
            <issue>6</issue>
            <fpage>813</fpage>
            <page-range>813-9</page-range>
            <pub-id pub-id-type="pmid">11171788</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42956.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sipahi</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Tuzcu</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Wolski</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Nicholls</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Schoenhagen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Balog</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Shishehbor</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Magyar</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Crowe</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Kapadia</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nissen</surname>
                <given-names>SE</given-names>
              </name>
            </person-group>
            <article-title>Beta-blockers and progression of coronary atherosclerosis: pooled analysis of 4 intravascular ultrasonography trials.</article-title>
            <source>Ann Intern Med</source>
            <year>2007</year>
            <month>Jul</month>
            <day>03</day>
            <volume>147</volume>
            <issue>1</issue>
            <fpage>10</fpage>
            <page-range>10-8</page-range>
            <pub-id pub-id-type="pmid">17606956</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42956.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carnagarin</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kiuchi</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Matthews</surname>
                <given-names>VB</given-names>
              </name>
              <name>
                <surname>Schlaich</surname>
                <given-names>MP</given-names>
              </name>
            </person-group>
            <article-title>Sympathetic Nervous System Activation and Its Modulation: Role in Atrial Fibrillation.</article-title>
            <source>Front Neurosci</source>
            <year>2018</year>
            <volume>12</volume>
            <fpage>1058</fpage>
            <pub-id pub-id-type="pmid">30728760</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42956.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sackner-Bernstein</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Mancini</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Rationale for treatment of patients with chronic heart failure with adrenergic blockade.</article-title>
            <source>JAMA</source>
            <year>1995</year>
            <month>Nov</month>
            <day>08</day>
            <volume>274</volume>
            <issue>18</issue>
            <fpage>1462</fpage>
            <page-range>1462-7</page-range>
            <pub-id pub-id-type="pmid">7474194</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42956.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Suzuki</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kunikane</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Shinno</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kozai</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kurata</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kawamura</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Ocular and Systemic Pharmacokinetics of Brimonidine and Timolol After Topical Administration in Rabbits: Comparison Between Fixed-Combination and Single Drugs.</article-title>
            <source>Ophthalmol Ther</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>115</fpage>
            <page-range>115-125</page-range>
            <pub-id pub-id-type="pmid">31953739</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42956.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Volotinen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hakkola</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pelkonen</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Vapaatalo</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>M&#x000e4;enp&#x000e4;&#x000e4;</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Metabolism of ophthalmic timolol: new aspects of an old drug.</article-title>
            <source>Basic Clin Pharmacol Toxicol</source>
            <year>2011</year>
            <month>May</month>
            <volume>108</volume>
            <issue>5</issue>
            <fpage>297</fpage>
            <page-range>297-303</page-range>
            <pub-id pub-id-type="pmid">21385322</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42956.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Salim</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Glaucoma in pregnancy.</article-title>
            <source>Curr Opin Ophthalmol</source>
            <year>2014</year>
            <month>Mar</month>
            <volume>25</volume>
            <issue>2</issue>
            <fpage>93</fpage>
            <page-range>93-7</page-range>
            <pub-id pub-id-type="pmid">24469077</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42956.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <collab>American College of Obstetricians and Gynecologists' Committee on Practice Bulletins&#x02014;Obstetrics</collab>
            <article-title>ACOG Practice Bulletin No. 203: Chronic Hypertension in Pregnancy.</article-title>
            <source>Obstet Gynecol</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>133</volume>
            <issue>1</issue>
            <fpage>e26</fpage>
            <page-range>e26-e50</page-range>
            <pub-id pub-id-type="pmid">30575676</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42956.r45">
          <label>45</label>
          <element-citation publication-type="book">
            <chapter-title>Timolol</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2022</year>
            <month>11</month>
            <day>30</day>
            <pub-id pub-id-type="pmid">30000225</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42956.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Krowchuk</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Frieden</surname>
                <given-names>IJ</given-names>
              </name>
              <name>
                <surname>Mancini</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Darrow</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Blei</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Greene</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Annam</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Baker</surname>
                <given-names>CN</given-names>
              </name>
              <name>
                <surname>Frommelt</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Hodak</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pate</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Pelletier</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Sandrock</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Weinberg</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Whelan</surname>
                <given-names>MA</given-names>
              </name>
              <collab>SUBCOMMITTEE ON THE MANAGEMENT OF INFANTILE HEMANGIOMAS</collab>
            </person-group>
            <article-title>Clinical Practice Guideline for the Management of Infantile Hemangiomas.</article-title>
            <source>Pediatrics</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>143</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">30584062</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42956.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tiemann</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hein</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Infantile Hemangioma: A Review of Current Pharmacotherapy Treatment and Practice Pearls.</article-title>
            <source>J Pediatr Pharmacol Ther</source>
            <year>2020</year>
            <volume>25</volume>
            <issue>7</issue>
            <fpage>586</fpage>
            <page-range>586-599</page-range>
            <pub-id pub-id-type="pmid">33041713</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42956.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Denys</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Cai</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Kapusta</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Lv</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Complete atrioventricular block due to timolol eye drops: a case report and literature review.</article-title>
            <source>BMC Pharmacol Toxicol</source>
            <year>2019</year>
            <month>Dec</month>
            <day>02</day>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>73</fpage>
            <pub-id pub-id-type="pmid">31791399</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42956.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mukherjee</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Giratkar</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Cicatricial ectropion due to allergic dermatitis.</article-title>
            <source>Oman J Ophthalmol</source>
            <year>2021</year>
            <season>May-Aug</season>
            <volume>14</volume>
            <issue>2</issue>
            <fpage>126</fpage>
            <page-range>126-127</page-range>
            <pub-id pub-id-type="pmid">34345152</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42956.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hommer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hubatsch</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Cano-Parra</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Safety and Efficacy of Adding Fixed-Combination Brinzolamide/Timolol Maleate to Prostaglandin Therapy for Treatment of Ocular Hypertension or Glaucoma.</article-title>
            <source>J Ophthalmol</source>
            <year>2015</year>
            <volume>2015</volume>
            <fpage>131970</fpage>
            <pub-id pub-id-type="pmid">26495134</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42956.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Negri</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ferreras</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Iester</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Timolol 0.1% in Glaucomatous Patients: Efficacy, Tolerance, and Quality of Life.</article-title>
            <source>J Ophthalmol</source>
            <year>2019</year>
            <volume>2019</volume>
            <fpage>4146124</fpage>
            <pub-id pub-id-type="pmid">31191995</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42956.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sica</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Current concepts of pharmacotherapy in hypertension--ophthalmically administered beta blockers and their cardiopulmonary effects.</article-title>
            <source>J Clin Hypertens (Greenwich)</source>
            <year>2001</year>
            <season>May-Jun</season>
            <volume>3</volume>
            <issue>3</issue>
            <fpage>175</fpage>
            <page-range>175-8</page-range>
            <pub-id pub-id-type="pmid">11416704</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42956.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ishiguro</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Fujita</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Omori</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Fujii</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Mayama</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sato</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Assessing the effects of non-steroidal anti-inflammatory drugs on antihypertensive drug therapy using post-marketing surveillance database.</article-title>
            <source>J Epidemiol</source>
            <year>2008</year>
            <volume>18</volume>
            <issue>3</issue>
            <fpage>119</fpage>
            <page-range>119-24</page-range>
            <pub-id pub-id-type="pmid">18469490</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42956.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Minish</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Herd</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Symptomatic bradycardia secondary to interaction between topical timolol maleate, verapamil, and flecainide: a case report.</article-title>
            <source>J Emerg Med</source>
            <year>2002</year>
            <month>Apr</month>
            <volume>22</volume>
            <issue>3</issue>
            <fpage>247</fpage>
            <page-range>247-9</page-range>
            <pub-id pub-id-type="pmid">11932086</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42956.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Handler</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Adverse effects using combined rate-slowing antihypertensive agents.</article-title>
            <source>J Clin Hypertens (Greenwich)</source>
            <year>2011</year>
            <month>Jul</month>
            <volume>13</volume>
            <issue>7</issue>
            <fpage>529</fpage>
            <page-range>529-32</page-range>
            <pub-id pub-id-type="pmid">21762367</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42956.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Taniguchi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kitazawa</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>The potential systemic effect of topically applied beta-blockers in glaucoma therapy.</article-title>
            <source>Curr Opin Ophthalmol</source>
            <year>1997</year>
            <month>Apr</month>
            <volume>8</volume>
            <issue>2</issue>
            <fpage>55</fpage>
            <page-range>55-8</page-range>
            <pub-id pub-id-type="pmid">10168358</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42956.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lasser</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Allen</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Woolhandler</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Himmelstein</surname>
                <given-names>DU</given-names>
              </name>
              <name>
                <surname>Wolfe</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Bor</surname>
                <given-names>DH</given-names>
              </name>
            </person-group>
            <article-title>Timing of new black box warnings and withdrawals for prescription medications.</article-title>
            <source>JAMA</source>
            <year>2002</year>
            <month>May</month>
            <day>01</day>
            <volume>287</volume>
            <issue>17</issue>
            <fpage>2215</fpage>
            <page-range>2215-20</page-range>
            <pub-id pub-id-type="pmid">11980521</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42956.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chantra</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hathaisaard</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Grzybowski</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ruamviboonsuk</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Microbial contamination of multiple-dose preservative-free hospital ophthalmic preparations in a tertiary care hospital.</article-title>
            <source>Adv Ophthalmol Pract Res</source>
            <year>2022</year>
            <season>May-Jun</season>
            <volume>2</volume>
            <issue>1</issue>
            <fpage>100046</fpage>
            <pub-id pub-id-type="pmid">37846225</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42956.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chaves-Samaniego</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Molina Lespron</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cervera Sanchez</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Amat Peral</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ruiz Moreno</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Bilateral Choroidal Detachment in the Absence of Previous Intraocular Surgery.</article-title>
            <source>Case Rep Ophthalmol</source>
            <year>2022</year>
            <season>Sep-Dec</season>
            <volume>13</volume>
            <issue>3</issue>
            <fpage>711</fpage>
            <page-range>711-716</page-range>
            <pub-id pub-id-type="pmid">36845455</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42956.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosin</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Bell</surname>
                <given-names>NP</given-names>
              </name>
            </person-group>
            <article-title>Preservative toxicity in glaucoma medication: clinical evaluation of benzalkonium chloride-free 0.5% timolol eye drops.</article-title>
            <source>Clin Ophthalmol</source>
            <year>2013</year>
            <volume>7</volume>
            <fpage>2131</fpage>
            <page-range>2131-5</page-range>
            <pub-id pub-id-type="pmid">24204115</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42956.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Teerlink</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Alburikan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Metra</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rodgers</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>Acute decompensated heart failure update.</article-title>
            <source>Curr Cardiol Rev</source>
            <year>2015</year>
            <volume>11</volume>
            <issue>1</issue>
            <fpage>53</fpage>
            <page-range>53-62</page-range>
            <pub-id pub-id-type="pmid">24251454</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42956.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huang</surname>
                <given-names>YL</given-names>
              </name>
              <name>
                <surname>Lai</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Impact of selective and nonselective beta-blockers on the risk of severe exacerbations in patients with COPD.</article-title>
            <source>Int J Chron Obstruct Pulmon Dis</source>
            <year>2017</year>
            <volume>12</volume>
            <fpage>2987</fpage>
            <page-range>2987-2996</page-range>
            <pub-id pub-id-type="pmid">29066880</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42956.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Crescioli</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Finocchietti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Paoletti</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Brunori</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sciancalepore</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Tuccori</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Addis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vannacci</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lombardi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kirchmayer</surname>
                <given-names>U</given-names>
              </name>
              <collab>CAESAR study group</collab>
            </person-group>
            <article-title>Potentially inappropriate drug use in myasthenia gravis: a real-world population-based cohort study in Italy.</article-title>
            <source>Front Neurol</source>
            <year>2023</year>
            <volume>14</volume>
            <fpage>1293626</fpage>
            <pub-id pub-id-type="pmid">38178892</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42956.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carnovale</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gringeri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Battini</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Mosini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Invernizzi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mazhar</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bergamaschi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Fumagalli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zuccotti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Clementi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Radice</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fabiano</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Beta-blocker-associated hypoglycaemia: New insights from a real-world pharmacovigilance study.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2021</year>
            <month>Aug</month>
            <volume>87</volume>
            <issue>8</issue>
            <fpage>3320</fpage>
            <page-range>3320-3331</page-range>
            <pub-id pub-id-type="pmid">33506522</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42956.r65">
          <label>65</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Khalid</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Galuska</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Hamilton</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <chapter-title>Beta-Blocker Toxicity</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>28</day>
            <pub-id pub-id-type="pmid">28846217</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42956.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cole</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Arens</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Laes</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Bangh</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Olives</surname>
                <given-names>TD</given-names>
              </name>
            </person-group>
            <article-title>High dose insulin for beta-blocker and calcium channel-blocker poisoning.</article-title>
            <source>Am J Emerg Med</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>36</volume>
            <issue>10</issue>
            <fpage>1817</fpage>
            <page-range>1817-1824</page-range>
            <pub-id pub-id-type="pmid">29452919</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
